Replies to post #241772 on Biotech Values

[DewDiligence]

NVS’ 2017 entry into radioligand field:

https://www.reuters.com/article/us-novartis-advanced-accelerator/novartis-to-buy-french-cancer-specialist-aaa-for-3-9-billion-idUSKBN1CZ0HC

NVS acquired AAAP in Oct 2017, thereby gaining ownership of Lutathera, a radioligand for neuroendocrine tumors. NVS paid a 47% premium in an all-cash deal valued at $3.9B.